Giuseppe Lombardi, Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS, shared on LinkedIn:
“New publication in Nature Communications!
Pleased to have contributed to the ARCAGEN study, an EORTC-SPECTA and EURACAN initiative exploring molecular profiling and access to personalized treatments for rare cancers across Europe, including tumors of the central nervous system.
Among 893 evaluable patients, 69.4% had actionable molecular alterations, but only 15% received a matched targeted therapy or immunotherapy.
These findings confirm the potential of comprehensive genomic profiling, while highlighting the persistent gap between identifying a therapeutic target and ensuring real access to treatment.
A strong message in support of earlier molecular testing, wider access to clinical trials and stronger European collaboration for patients with rare cancers.”
Title: Molecular profiling and access to treatment for rare cancers in Europe
Authors: M. Morfouace, F. Hoogstoel, J. Oliveira, N. Penel, S. Tejpar, I. Ray-Coquard, J. Peron, M. Pracht, B. Brasiuniene, A. Capela, C. Gennigens, L. Greillier, C. Even, R. Huang, T. Gorlia, G. Lombardi, M. Gamulin, L. Licitra, N. Girard, H. J. Klümpen, A. Idbaih, WTA Van der Graaf, J. Y. Blay
Other articles featuring Giuseppe Lombardi on OncoDaily.